Boehringer gets priority review for lung cancer drug; Astex and Cancer Research UK partner on PhI;

Conversations on Twitter :

 @FierceBiotech: Popular yesterday: Buzz: $AZN reorg inspires fresh rumors of $SHPG bid. Report | Follow @FierceBiotech

@JohnCFierce: Columnist gushes over Inovio's Kim, a tireless promoter whose stock is trading at .67 and whose flu vax is in PhI. Column | Follow @JohnCFierce

@RyanMFierce: $EXEL's plethora of partnerships bearing fruit as Genentech moves melanoma drug from EXEL into PhIII. More | Follow @RyanMFierce

> The FDA has agreed to provide a priority review for Boehringer Ingelheim's cancer drug afatinib, now under review for non-small cell lung cancer. Release

> Astex Pharmaceuticals in Dublin, CA, and Cancer Research UK have begun a Phase I study of AT13148, which has shown promise for shutting down a number of enzymes that control cancer cell growth. Release

> Janssen Research & Development, a unit of Johnson & Johnson ($JNJ), forked over an undisclosed milestone payment to partner Xencor because Janssen decided to use the Monrovia, CA-based biotech's technology for making an antibody drug last longer in a patient's system. Release

Pharma News

@FiercePharma: Bond market pants for Pfizer vet unit's debut offering: Zoetis sets up $3.65B in debt amid final prep for IPO. More | Follow @FiercePharma

 @AlisonBFierce: FierceVaccines brings you the major FDA vaccine approvals from 2012. Special Report | Follow @AlisonBFierce

> Aranesp flunks heart-failure trial, raising new questions about use. News

> MedImmune unit split 3 ways in AstraZeneca shake-up. More

> AARP, AFL-CIO and prominent docs to White House: Get us the sunshine rules, stat. Story

Vaccines News

> IOM confirms safety of childhood vaccine schedule. Report

> CDC: Flu hits epidemic level in U.S. Item

> Protein Sciences nabs Flublok approval. News

> Vaccine stakes upped as dengue dubbed fastest-spreading tropical disease. Article

> Flu vaccine, Tamiflu shortage as influenza sweeps U.S. Story

Pharma Manufacturing News

 @EricPFierce: Amgen to build $200 million monoclonal antibody plant in Singapore. Novartis building there too. More | Follow @EricPFierce

> Wisconsin report adds to drug take-back funding debate. Item

> China ups bounty for tips on counterfeiters to $48,500. Report

> Japan's Mitsui ups stake in India API maker Arch. Story

> FDA spells out user fees for generic drugs. Article

> J&J consent decree cost felt at the pharmacy. More

And Finally… Peter K. Gregersen, Robert J. Winchester, and Lars Klareskog of the Karolinska Institute have won the prestigious Crafoord Prize in Polyarthritis from the Royal Swedish Academy of Sciences. They'll split a $618,000 prize. Story

 

Suggested Articles

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.

FDA staff took the action in response to cases of early growth plate closure in children on the retinoic acid receptor gamma agonist.

The CTAD presentation cleared up some questions about the data set without delivering a telling blow for either side of the debate.